乳腺癌TKI治疗幻灯课件.pptVIP

乳腺癌TKI治疗 2010ASCO;内容;Sunitinib in Combination with Docetaxel vs. Docetaxel Alone for the First-line Treatment of Advanced Breast Cancer;Rationale;SUN 1064 Design;Europe;Endpoints and Statistical Hypothesis;Patient Characteristics (ITT Population) ;Treatment Administration (AT Population);Objective Response in Patients with Measurable Disease;Patients at risk;Overall Survival (ITT Population);Common All-Causality AEs (AT Population); AEs Leading to Treatment Discontinuation in ≥2% of Pts in Either Arm (AT Population);Fatalities;Conclusions;Phase 3 Trial of Sunitinib in